4.7 Review

GLP-1 mimetics and cognition

Journal

LIFE SCIENCES
Volume 264, Issue -, Pages -

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.lfs.2020.118645

Keywords

Glucagon-like peptide-1; Incretins; Diabetes mellitus; Cognition; Memory; Alzheimer's disease

Ask authors/readers for more resources

GLP-1 receptor agonists not only improve glycemic control, but also have potential benefits in improving cognitive performance through multiple molecular mechanisms, which could be particularly beneficial for diabetic patients with cognitive impairments.
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic drugs that improve the glycaemia via several molecular pathways. Recent evidence suggest that they also have additional effects modulating pathophysiologic pathways included in cognitive disorders. Since some forms of cognitive dysfunction such as Alzheimer's disease are more common among diabetic patients than in the normal population, antidiabetic drugs that have neuroprotective effects affording protection for cognitive disorders would be of benefit. Therefore, we reviewed the pharmacologic effects of GLP-1 analogues and found that they may have the additional benefit of improving cognitive performance via at least eight molecular mechanisms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available